Covid Shots Could Run $225 for Many Americans Under RFK Jr. Plan

The FDA's recent narrowing of Covid-19 booster approvals to specific high-risk groups and seniors 65+ is projected to constrain vaccine availability and likely increase costs for many Americans this fall. This regulatory shift, impacting Moderna, Pfizer, and Novavax boosters, suggests a more limited and potentially more expensive market for Covid-19 vaccinations outside of the approved demographics.

Analysis

The U.S. Food and Drug Administration's decision to narrow its approval for Covid-19 boosters represents a significant regulatory shift impacting vaccine manufacturers Moderna (MRNA), Pfizer (PFE), and Novavax (NVAX). By restricting eligibility primarily to seniors aged 65 and older and individuals with specific high-risk conditions, the addressable market for the fall vaccination season has been materially reduced compared to previous, broader campaigns. This move is projected to constrain vaccine availability and likely lead to higher costs for the general population not covered under the new approvals. The market's reaction, indicated by a uniform, slightly negative sentiment score (-0.2) for all three companies, reflects the revised, more limited commercial opportunity. The overall pessimistic tone of the report (-0.6 sentiment score) is driven by the implications of constrained public access and higher consumer costs, though the low market impact score (0.3) suggests this is not viewed as a major shock to the companies' overall financial standing.

Key Decisions for Investors

• Investors in MRNA, PFE, and NVAX should revise near-term revenue forecasts for Covid-19 boosters downward to account for the smaller, more targeted eligible population in the U.S.
• The key variables to monitor are the commercial pricing models these companies adopt and the actual uptake rates within the newly defined eligible groups, as these will determine the ultimate financial impact of the regulatory change.
• This development presents a more significant headwind for companies with higher revenue concentration from their Covid-19 franchise, such as Moderna and Novavax, compared to the more diversified portfolio of Pfizer.